alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
ex_177931.htm


Exhibit 10.10


 


FORM OF


FIRST AMENDMENT TO 


LICENSE AGREEMENT NO. A9672


 


WHEREAS, the University of Florida Research Foundation, Inc., a not-for-profit corporation duly organized and existing under the laws of the State of Florida and having its principal office at 223 Grinter Hall, Gainesville, Florida 32611 U.S.A. (hereinafter referred to as "UFRF"), and Sun BioPharma, Inc., a Delaware corporation, and having its principal mailing address at 712 Vista Blvd, #305, Waconia, MN 55387, (hereinafter referred to as "Licensee") entered into a License Agreement effective December 22, 2011 (hereinafter "License Agreement");


 


WHEREAS, the parties now wish to amend the License Agreement;


 


NOW THEREFORE, in consideration of the premises and mutual covenants contained herein the parties hereto agree as follows;


 


	
			1.

				
			At the time of the writing of this First Amendment, Licensee owes a balance of $20,000 on the milestone payment of $50,000 for the "Enrollment of first subject in Phase I Trial".

			



 


	
			2.

				
			UFRF and Licensee agree that Licensee will pay the remaining balance of $20,000 within thirty (30) days of receipt of its next $2M in fundraising occurring subsequent to the date of this First Amendment to the License Agreement.

			



 


	
			3.

				
			All other provisions of the License Agreement shall remain in full force and effect and unmodified by this Amendment.

			



 


	
			4.

				
			This amendment shall be effective December 12, 2016 and shall be referred to as the First Amendment.

			



 


UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.


 


	By:	 	 	 
	David L. Day	 	 
	Director of Technology Licensing	 	 
	Date:	 	 	 



 


SUN BIOPHARMA, INC.


 



	By:	 	 
	Name:	 	 
	Title:	 	 
	Date:
#### STATE v. PEARCY

No. 53PC

Case below: 50 NC App 210

Application by defendant for further review denied 7 April 1981.
/LfO.

Jl,U TAc~

AosTiKf* rems M 26 20|5

^ Abel Acosta, Clerk

TAe^m TS Of "6**5 FILED IN

COURT OF CRIMINAL APPEALS

JUN 26 201b

TA^)^ 4 LTT COOaJ TV . TBXAS. Abel Acosta, Clerk

(CPVD5c PETiTlOk5£#*b Fi^OrMOTtOkf r£>&) eXTaLySlOkf Or TiMg

TO Fijlc Pcr/HO/J'rb^ J3\3CK£r\CnSf\®rl ^cu/euT

TO THE hld/irOQH3-L6 3UI3C&5 OPSA i a COU^TOFCPiiAAlilAjLAPP&MiD I

c&wsdnour,^arr^\o<znc5^jj^i\t petitioner', Prfrocand-fUeo

uJn'iCh to Pi ie^j pro se perirtDKf fc/*> ni3c*enoAj*<Vi &>e\ji£\a). zn

ScjP-f>c>r~r a-f *-ho proac motion, appei\ontS^ocas +ine Courime Pe-rl+'ioner uj&s conuiei-eci in tnecnm\noi u&pmctcDu^t

ujM^ePi oue. op Torrent county, tcxgo.o^ -rhe o^^eoscOf

/VkjrzJer-/ in COu3C U0.O3-V&-J<56>-jJ. 5t-N//cJ, jTATcOrfSx/t5( VS

d&rry Gene ^euJeiL nne Peti tior^rJ aPPeciiccJ ?o -thc5econd

Supreme ~aoiaa i ai^tnct- ccxjtterf Appear, fbr-t uJorthJ&as.

rhe OZ5C Lujas APVrrncd oe 5ePtemicer i /, K/8G. £ QPose Pn<\

l^jcls ftei-dOecJ.u/Un/Ufc^/J. 5jd5e<Puco^'v// Pe-tt-hcDcr -filed

a Pro Se A/i£>r/OAj: redD<_je5*->0£/ -h-£> criminal Qhtr-ict ccurt-'

UcjmhcTone.o-erorrant county. 7exo5( to uuui^ltorti^d'
Exhibit 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Kewaunee Scientific Corporation (the Company) for the
period ended January 31, 2009, I, William A. Shumaker, President and Chief Executive Officer of the Company, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that
to my knowledge:



| | (1) | such Form 10-Q of the Company for the period ended January 31, 2009, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
| | --- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | (2) | the information contained in such Form 10-Q of the Company for the period ended January 31, 2009, fairly presents, in all material respects, the financial condition and results
of operations of the Company.
| | --- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Date: March 10, 2009



/s/ William A. ShumakerWilliam A. ShumakerPresident and Chief Executive Officer
Case 1:07-cv-03493-CM Document 5 Filed 05/04/2007 Page 1 of 8
Case 1:07-cv-03493-CM Document 5 Filed 05/04/2007 Page 2 of 8
Case 1:07-cv-03493-CM Document 5 Filed 05/04/2007 Page 3 of 8
Case 1:07-cv-03493-CM Document 5 Filed 05/04/2007 Page 4 of 8
Case 1:07-cv-03493-CM Document 5 Filed 05/04/2007 Page 5 of 8
Case 1:07-cv-03493-CM Document 5 Filed 05/04/2007 Page 6 of 8
Case 1:07-cv-03493-CM Document 5 Filed 05/04/2007 Page 7 of 8
Case 1:07-cv-03493-CM Document 5 Filed 05/04/2007 Page 8 of 8
#### WILLIAMS v. DAMERON

No. 40 PC.

Case below: 37 N.C. App. 491.

Petition by plaintiff for discretionary review under G.S. 7A-31 denied 4 October 1978. Motion of defendant to dismiss appeal for lack of substantial constitutional question allowed 4 October 1978.
Case 7:07-cv-03537-CLB Document 1 Filed 05/03/2007 Page 1 of 6
Case 7:07-cv-03537-CLB Document 1 Filed 05/03/2007 Page 2 of 6
Case 7:07-cv-03537-CLB Document 1 Filed 05/03/2007 Page 3 of 6
Case 7:07-cv-03537-CLB Document 1 Filed 05/03/2007 Page 4 of 6
Case 7:07-cv-03537-CLB Document 1 Filed 05/03/2007 Page 5 of 6
Case 7:07-cv-03537-CLB Document 1 Filed 05/03/2007 Page 6 of 6
|   | 1.   | the Report fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and |
|--------|----------------|----------------------------------------------------------------------------------------------------|

|   | 2.   | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of CNOOC Limited. |
|--------|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |           |
|--------|----------------|
| By:    | /s/ Fanrong Li |   |
|   | Name:          | Fanrong Li |   |
|   | Title:         | Chief Executive Officer and President |   |

|   |          |
|--------|---------------|
| By:    | /s/ Hua Zhong |   |
|   | Name:         | Hua Zhong |   |
|   | Title:        | Chief Financial Officer |   |
Exhibit 11

                         AUTOINFO, INC. AND SUBSIDIARIES

                        Calculation of Earnings Per Share

<TABLE>
<CAPTION>
                                                       Year ended          Seven Months         Year Ended
                                                      December 31,       Ended December 31,      May 31,
                                                          1996                1995                1995
                                                      ------------         -----------         -----------
<S>                                                   <C>                  <C>                 <C>
Primary and fully diluted earnings (loss):
 Income (loss) from continuing operations             $(19,099,501)        $   560,672         $(2,078,126)
 Income (loss) from discontinued operations                   --               (28,163)          1,518,659
 Gain on sale of discontinued operations                      --               296,839           8,885,688
                                                      ------------         -----------         -----------
 Earnings (loss) from operations applicable to
   common stock                                       $(19,099,501)        $   829,348         $ 8,326,221
                                                      ------------         -----------         -----------

Shares:
  Weighted average number of common
     shares outstanding                                  7,920,515           7,765,261           7,307,657
   Added shares issuable from assumed
     exercise of options                                      --                 5,656             102,891
                                                      ------------         -----------         -----------
   Weighted average number of common
     shares as adjusted                                  7,920,515           7,770,917           7,410,548
                                                      ------------         -----------         -----------

Primary and fully diluted earnings (loss):
   From continuing operations                         $      (2.41)        $       .07         $      (.28)

   From discontinued operations                               --                  --                   .21
   From gain on sale of discontinued
     operations                                               --                   .04                1.19
                                                      ------------         -----------         -----------

Earnings (loss) per common share                      $      (2.41)        $       .11         $      1.12
                                                      ============         ===========         ===========
</TABLE>
Case 1:06-cv-15069-AKH Document 5 Filed 12/08/2006 Page 1 of 1
| /s/  David      L.      Cheek                                                                    David      L. CheekPresident      and Chief Executive OfficerMay      9, 2008 | /s/  Bert E. Downing,      Jr.                                                                          Bert      E. Downing, Jr.Vice      President, Chief Financial Officer,Corporate      Controller and TreasurerMay      9, 2008 |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
Case 1:07-cv-03496-WHP Document 16-40 Filed 06/20/2007 Page 1 of 25
Case 1:07-cv-03496-WHP Document 16-40 Filed 06/20/2007 Page 2 of 25
Case 1:07-cv-03496-WHP Document 16-40 Filed 06/20/2007 Page 3 of 25
Case 1:07-cv-03496-WHP Document 16-40 Filed 06/20/2007 Page 4 of 25
Case 1:07-cv-03496-WHP Document 16-40 Filed 06/20/2007 Page 5 of 25
Case 1:07-cv-03496-WHP Document 16-40 Filed 06/20/2007 Page 6 of 25
Case 1:07-cv-03496-WHP Document 16-40 Filed 06/20/2007 Page 7 of 25
Case 1:07-cv-03496-WHP Document 16-40 Filed 06/20/2007 Page 8 of 25
Case 1:07-cv-03496-WHP Document 16-40 Filed 06/20/2007 Page 9 of 25
Case 1:07-cv-03496-WHP Document 16-40 Filed 06/20/2007 Page 10 of 25
Case 1:07-cv-03496-WHP Document 16-40 Filed 06/20/2007 Page 11 of 25
Case 1:07-cv-03496-WHP Document 16-40 Filed 06/20/2007 Page 12 of 25
Case 1:07-cv-03496-WHP Document 16-40 Filed 06/20/2007 Page 13 of 25
Case 1:07-cv-03496-WHP Document 16-40 Filed 06/20/2007 Page 14 of 25
Case 1:07-cv-03496-WHP Document 16-40 Filed 06/20/2007 Page 15 of 25
Case 1:07-cv-03496-WHP Document 16-40 Filed 06/20/2007 Page 16 of 25
Case 1:07-cv-03496-WHP Document 16-40 Filed 06/20/2007 Page 17 of 25
Case 1:07-cv-03496-WHP Document 16-40 Filed 06/20/2007 Page 18 of 25
Case 1:07-cv-03496-WHP Document 16-40 Filed 06/20/2007 Page 19 of 25
Case 1:07-cv-03496-WHP Document 16-40 Filed 06/20/2007 Page 20 of 25
Case 1:07-cv-03496-WHP Document 16-40 Filed 06/20/2007 Page 21 of 25
Case 1:07-cv-03496-WHP Document 16-40 Filed 06/20/2007 Page 22 of 25
Case 1:07-cv-03496-WHP Document 16-40 Filed 06/20/2007 Page 23 of 25
Case 1:07-cv-03496-WHP Document 16-40 Filed 06/20/2007 Page 24 of 25
Case 1:07-cv-03496-WHP Document 16-40 Filed 06/20/2007 Page 25 of 25
215 N.
Pine St.
 P. O. Box
3508
 Spartanburg,
SC  29304
 (864)
948-9001








April 30,
2009








Mr.
Linwood Gill


Vice
President


Federal
Reserve Bank of Richmond


P.O. Box
27622


Richmond,
VA 23261





Dear Mr.
Gill:





Our subsidiary bank, First National
Bank of the South, executed a consent order with its primary regulator, the OCC,
on April 27, 2009.  Included in this consent order is an article that
does not allow the bank to be classified as “well-capitalized,” regardless of
its capital levels while the bank is subject to the terms of the
order.  As a result, we understand that we are not in compliance with
the requirements to maintain our status as a financial holding
company.  Therefore, we are writing you this letter to decertify First
National Bancshares as a financial holding company.





The
nonbanking activities that we are involved in are limited to ownership of common
securities of our three statutory trust subsidiaries, FNSC Capital Trust I, FNSC
Statutory Trust II and FNSC Statutory Trust III.  It is our
understanding that our participation in these Trusts is permissible for a bank
holding company and that no changes to our role in these Trusts will be required
as a result of our request to decertify.  We also understand that our
ownership of other debt and equity securities is permissible as a bank holding
company and that no changes to this ownership will be required.





Please do not hesitate to contact me
should you require additional information with regard to our decertification
request.  Please confirm your receipt of this request by signing this
letter below and returning in the enclosed envelope.





Sincerely,





/s/ Jerry
L. Calvert_________


Jerry L. Calvert


President and Chief Executive
Officer


First National Bancshares





Received
by:








_________________________


Name





_________________________


Date
VANGUARD HEALTH SYSTEMS, INC.



EXHIBIT 10.1


Approved by the Board of Directors on August 18, 2009


AMENDMENT NUMBER 7



to the



VANGUARD HEALTH SYSTEMS, INC.

2004 STOCK INCENTIVE PLAN


            The first sentence of Section 3 of the above-referenced Plan is deleted in its entirety and replaced with the following new sentence:


                        “The total number of Shares which may be issued under the Plan is 145,611.”
# Fourth Court of Appeals

**San Antonio, Texas**

September 26, 2014

N o. 04

- 14

- 00397

- CV

IN THE INTEREST OF S.D.A., S.A.A., D.S.A., Children,

From the 37th Judicial District Court, Bexar County, Texas

Trial Court No. 2013EM506191

Honorable Eric Rodriguez, Judge Presiding



### ORDER

The Appellant ’ s Request for Extension of Time to File Brief is GRANTED. The

appellant ’ s brief is due on October 13, 2014.

_________________________________ Rebeca C. Martinez, Justice

IN WITNESS WHEREOF, I have here unto set my hand and affixed the seal of the said

court on this 26th day of September, 2014

.

___________________________________ Keith E. Hottle

Clerk of Court
#### TRULL v. McINTYRE

No. 53 PC

Case below: 48 NC App 599

Petition by plaintiff for discretionary review under G.S. 7A-31 denied 2 December 1980.
Parker-Hannifin Corporation Claw-Back Policy



 Exhibit 10.2 
 

 
 PARKER-HANNIFIN CORPORATION 
 Claw-back Policy 
 NOW, THEREFORE, BE IT RESOLVED, that the Corporation hereby
adopts a claw-back policy on the following terms and conditions, effective with respect to annual incentives or other performance-based compensation granted or paid on or after July 1, 2009: 
 Each Officer shall repay or forfeit, to the fullest extent provided by law, any annual incentive or other performance-based compensation, including RONA,
Target Incentive, and LTIP bonus payments received by him or her if: 
  

	 	•	 	 the payment, grant or vesting of such compensation was based on the achievement of financial results that were subsequently the subject of a restatement of the
Corporation’s financial statements filed with the Securities and Exchange Commission, 


  

	 	•	 	 the Board determines in its sole discretion, exercised in good faith, that the Corporate Officer engaged in fraud or misconduct that caused or contributed to the
need for the restatement, 


  

	 	•	 	 the amount of the compensation that would have been received by the Corporate Officer had the financial results been properly reported would have been lower than
the amount actually received, and 


  

	 	•	 	 the Board determines in its sole discretion that it is in the best interests of the Corporation and its stockholders for the Corporate Officer to repay or forfeit
all or any portion of the compensation. 


 The Board, acting solely by the independent Directors as identified under the
applicable exchange listing standards, shall have full and final authority to make all determinations under this policy, including without limitation whether the policy applies and if so, the amount of compensation to be repaid or forfeited by the
Corporate Officer. All determinations and decisions made by the Board pursuant to the provisions of this policy shall be final, conclusive and binding on all persons, including the Corporation, its affiliates, its stockholders and employees.

 From and after July 1, 2009, each award agreement or other document setting forth the terms and conditions of any annual incentive or
other performance-based award granted to a Corporate Officer shall include a provision incorporating the requirements of this policy. The remedy specified in this policy shall not be exclusive and shall be in addition to every other right or remedy
at law or in equity that may be available to the Corporation.
<PAGE>

                                                                    EXHIBIT 32.2


                            CERTIFICATION PURSUANT TO
                 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection with the Annual Report on Form 10-K of Northern Border Pipeline
Company (the "Partnership") for the year ended December 31, 2004 as filed with
the Securities and Exchange Commission on the date hereof (the "Report"), Jerry
L. Peters, Vice President, Finance and Treasurer, of Northern Plains Natural Gas
Company, Operator (functional equilavent to the Partnership's principal
financial and accounting officer), hereby certifies, pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, that:

      (1)   The Report fully complies with the requirements of section 13(a) or
            section 15(d), as applicable, of the Securities Exchange Act of
            1934; and

      (2)   The information contained in the Report fairly presents, in all
            material respects, the financial condition and results of operations
            of the Partnership.


Dated: March 11, 2005                 /s/ Jerry L. Peters
                                    ---------------------------------
                                          Jerry L. Peters
                                          Vice President, Finance and Treasurer
                                          Northern Plains Natural Gas Company


This certification is made solely for the purpose of 18 U.S.C. Section 1350, and
not for any other purpose.
#### AUSTIN v. ROYALL

No. 87 PC.

Case below: 38 N.C. App. 118.

Petition by defendants for discretionary review under G.S. 7A-31 denied 3 November 1978.
[Federal Register Volume 70, Number 232 (Monday, December 5, 2005)]
[Notices]
[Pages 72457-72458]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 05-23588]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Center for Scientific Review; Notice of Meeting

    Pursuant to section 10(a) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the National 
Institutes of Health Peer Review Advisory Committee.
    The meeting will be open to the public, with attendance limited to 
space available. Individuals who plan to attend and need special 
assistance, such as sign language interpretation or other reasonable 
accommodations, should

[[Page 72458]]

notify the Contact Person listed below in advance of the meeting.

    Name of Committee: National Institutes of Health Peer Review 
Advisory Committee.
    Date: January 23, 2006.
    Time: 8 a.m. to 5 p.m.
    Agenda: Provide technical and scientific advice to the Director, 
National Institutes of Health (NIH), the Deputy Director for 
Extramural Research, NIH and the Director, Center for Scientific 
Review (CSR), on matters relating broadly to review procedures and 
policies for the evaluation of scientific and technical merit of 
applications for grants and awards.
    Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 
Wisconsin Avenue, Bethesda, MD 20814.
    Contact Person: Michael Martin, PhD., Executive Secretary, 
Center for Scientific Review, National Institutes of Health, 6701 
Rockledge Drive, Room 5198, MSC 7850, Bethesda, MD 20892. 301/594-
7945. <a href="/cdn-cgi/l/email-protection#731e1201071a1d1e331000015d1d1a1b5d141c05"><span class="__cf_email__" data-cfemail="e38e8291978a8d8ea3809091cd8d8a8bcd848c95">[email protected]</span></a>.
    Any interested person may file written comments with the 
committee by forwarding the statement to the Contact Person listed 
on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, 
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, 
National Institutes of Health, HHS)

    Dated: November 21, 2005.
Nancy Middendorf,
Acting Director, Office of Federal Advisory Committee Policy.
[FR Doc. 05-23588 Filed 12-2-05; 8:45 am]
BILLING CODE 4140-01-M


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
Case 7:07-cv-03432-CS-MDF Document 2 Filed 04/30/2007 Page 1 of 1
**Exhibit 31.3**

 

I, Edward D. Segal, certify that:

 

1. I have reviewed this annual report on Form 10-K/A of Metron TechnologyN.V.;

 

2. Based on my knowledge, this report doesnot contain any untrue statement of a material fact or omit to state a materialfact necessary to make the statements made, in light of the circumstances underwhich such statements were made, not misleading with respect to the periodcovered by this report;

 

Date: September 10, 2004

 

 
| /s/ EDWARD D.  SEGAL                  |   |
|---------------------------------------|--------|
| Edward D. Segal                       |
| Chairman and  Chief Executive Officer |

 

----